Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor

  title={Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor},
  author={Eric L. Moore and Mark E. Fraley and Ian M Bell and Christopher S. Burgey and Rebecca B. White and Chi-Chung Li and Christopher P. Regan and Andrew Danziger and Maria Michener and Eric D. Hostetler and Pradeep K. Banerjee and Christopher A. Salvatore},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  pages={160 - 166}
A growing body of evidence has implicated the calcitonin gene–related peptide (CGRP) receptors in migraine pathophysiology. With the approval of monoclonal antibodies targeting CGRP or the CGRP receptor, the inhibition of CGRP-mediated signaling emerged as a promising approach for preventive treatments of migraine in adults. Recently, small-molecule anti-CGRP treatments have shown efficacy for treating migraine. The current studies aimed to characterize the pharmacologic properties of… 

Tables from this paper

Antagonism of CGRP Signaling by Rimegepant at Two Receptors

The ability of rimegepant to antagonize activation of human CGRP, AMY1, and related adrenomedullin receptors was determined in transfected in Cos7 cells.

Migraine therapeutics differentially modulate the CGRP pathway

The therapeutic effect of agents targeting the CGRP ligand versus receptor for migraine prevention (antibodies) or acute treatment (gepants) may involve distinct mechanisms of action.

Gepants, calcitonin gene-related peptide antagonists, for abortive treatment of migraine: current status

Gepants do not have vasoconstrictive properties, are safe to use in patients with cardiovascular risk, and best alternative to triptan therapy, and are being evaluated for their effectiveness and showing promising results in the prevention of migraine.

Pharmacological characterisation of mouse calcitonin and calcitonin receptor‐like receptors reveals differences compared with human receptors

The calcitonin (CT) receptor family is complex, comprising two receptors (the CT receptor [CTR] and the CTR‐like receptor [CLR]), three accessory proteins (RAMPs) and multiple endogenous peptides.

CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?

The antagonists are most potent at the CGRP receptor but can also show antagonism of the AMY1 receptor, however, important data are missing and selectivity parameters cannot be provided for all antagonists.

Ubrogepant: a new era in migraine treatment

Ubrogepant is the first oral CGRP antagonist, that was approved by USFDA in December 2019, for the acute treatment of migraine with or without aura, and is more potent than the earlier C GRP receptor antagonists, has a good oral bioavailability and the risk of hepatotoxicity is also lesser than the previous Gepants.

Ubrogepant for the treatment of migraine

Ubrogepant, a selective CGRP antagonist belonging to the gepants family, has been evaluated in large short- and long-term clinical trials to assess clinical efficacy and safety as acute migraine medication and did not significantly affect liver function and was not associated with other serious adverse events.



Possible sites of action of the new calcitonin gene-related peptide receptor antagonists

The aim of this paper is to review recent localization studies of CGRP and its receptor components within the nervous system and to discuss whether these sites could be possible targets for the C GRP-receptor antagonists.

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

In vitro autoradiography studies on rhesus monkey brain slices identified the highest level of binding in the cerebellum, brainstem, and meninges, and the in vivo cerebrospinal fluid/plasma ratio was determined to be 2 to 3% in cisterna magna-ported rhesUS monkeys.

Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class

Data indicated that the therapeutic site of action of the CGRP‐RAs was peripheral not central; that IV C GRP had most likely evoked migraine through an action at sites outside the blood‐brain barrier; and that migraine pain was therefore, at least in part, peripheral in origin.

Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine

The crystal structure of the C GRP receptor ECD has been elucidated and not only reinforces the early mutagenesis data, but provides critical insight into the molecular mechanism of CGRP receptor antagonism.

Recognizing the role of CGRP and CGRP receptors in migraine and its treatment

The trigeminovascular system, located outside the BBB, has a key role in migraine symptomatology, and it is likely targeted by the novel CGRP drugs that successfully terminate migraine headache.

The CGRP Pathway in Migraine as a Viable Target for Therapies

If ongoing long‐term studies show that their efficacy can be maintained, this may herald a new era for effective antimigraine therapies.

Calcitonin gene-related peptide: physiology and pathophysiology.

It is concluded that CGRP is an important peptide in mammalian biology, but it is too early at present to know if new medicines for disease treatment will emerge from knowledge concerning this molecule.

In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232

Application of [11C]MK-4232 in human PET studies revealed that telcagepant achieved only low receptor occupancy at an efficacious dose (140 mg PO), therefore, it is unlikely that antagonism of central CGRP-R is required for migraine efficacy.

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

  • D. Dodick
  • Biology, Medicine
    Cephalalgia : an international journal of headache
  • 2019
Calcitonin gene-related peptide monoclonal antibodies are effective and well tolerated for the preventive treatment of migraine and have distinct advantages over currently available oral preventive drugs.